Literature DB >> 16286232

Breast cancer control: signs of progress, but more work required.

Peter Boyle1.   

Abstract

Breast cancer represents 10% of the global cancer burden and there is no population, or population sub-group, which has yet been identified to be at a truly low risk of developing the disease. Mortality rates have been steadily growing for nearly a century in many countries and it is only during the past decade that there have been signs of a sustainable decrease in mortality rates in a number of western-lifestyle countries. This represents considerable progress in breast cancer control and, although different factors contribute to different degrees in different countries, is mainly due to increased breast awareness, earlier detection and the delivery of the most appropriate therapy to women with the disease. The failure to prevent the incidence from continuing to rise represents to a great extent the failure to understand the precise mechanisms of breast carcinogenesis and the role of risk determinants whose alteration in society could lead to a reduced risk of developing the disease. The declines seen in mortality represent a considerable success, but there is no room for complacency until research can impact positively on reducing incidence.

Entities:  

Mesh:

Year:  2005        PMID: 16286232     DOI: 10.1016/j.breast.2005.10.001

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  10 in total

1.  Endocrine disruptor vinclozolin induced epigenetic transgenerational adult-onset disease.

Authors:  Matthew D Anway; Charles Leathers; Michael K Skinner
Journal:  Endocrinology       Date:  2006-09-14       Impact factor: 4.736

2.  Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy.

Authors:  Stefan A Lange; Bernd Ebner; Astrid Wess; Matthias Kögel; Mieczyslaw Gajda; Thomas Hitschold; Jens Jung
Journal:  Clin Res Cardiol       Date:  2012-01-17       Impact factor: 5.460

3.  In-vitro antiproliferative activity of benzopyranone derivatives in comparison with standard chemotherapeutic drugs.

Authors:  Musiliyu A Musa; John S Cooperwood; M Omar F Khan; Taufiq Rahman
Journal:  Arch Pharm (Weinheim)       Date:  2010-11-29       Impact factor: 3.751

4.  Synthesis and antiproliferative activity of coumarin-estrogen conjugates against breast cancer cell lines.

Authors:  Musiliyu A Musa; M Omar F Khan; John S Cooperwood
Journal:  Lett Drug Des Discov       Date:  2009-03       Impact factor: 1.150

5.  Incomplete pregnancy is not associated with breast cancer risk: the California Teachers Study.

Authors:  Katherine DeLellis Henderson; Jane Sullivan-Halley; Peggy Reynolds; Pamela L Horn-Ross; Christina A Clarke; Ellen T Chang; Susan Neuhausen; Giske Ursin; Leslie Bernstein
Journal:  Contraception       Date:  2008-04-18       Impact factor: 3.375

6.  Breast cancer risk assessment in socioeconomically disadvantaged urban communities.

Authors:  Chyongchiou Jeng Lin; Bruce Block; Mary Patricia Nowalk; Mattie Woods; Edmund M Ricci; Keith H Morgenlander; Dwight E Heron
Journal:  J Natl Med Assoc       Date:  2007-07       Impact factor: 1.798

7.  Awareness of Breast Cancer among Female Care Givers in Tertiary Cancer Hospital, China

Authors:  Negalign Getahun Dinegde; Li Xuying
Journal:  Asian Pac J Cancer Prev       Date:  2017-07-27

8.  HSPA5 Could Be a Prognostic Biomarker Correlated with Immune Infiltration in Breast Cancer.

Authors:  Chao Zhang; Qing Liu; Yubo Zhou; Jianfen Hua; Ruijun Su; Jun Ai
Journal:  Dis Markers       Date:  2022-09-20       Impact factor: 3.464

9.  The incidence rate of female breast cancer in Saudi Arabia: an observational descriptive epidemiological analysis of data from Saudi Cancer Registry 2001-2008.

Authors:  Ibrahim G Alghamdi; Issam I Hussain; Mohamed S Alghamdi; Mohamed A El-Sheemy
Journal:  Breast Cancer (Dove Med Press)       Date:  2013-10-17

10.  Clinical aspects of foot health and their influence on quality of life among breast cancer survivors: a case-control study.

Authors:  Patricia Palomo-López; David Rodríguez-Sanz; Ricardo Becerro-de-Bengoa-Vallejo; Marta Elena Losa-Iglesias; Jorge Guerrero-Martín; Cesar Calvo-Lobo; Daniel López-López
Journal:  Cancer Manag Res       Date:  2017-11-01       Impact factor: 3.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.